Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 142,916,672
  • Shares Outstanding, K 582,169
  • Annual Sales, $ 23,362 M
  • Annual Income, $ 7,842 M
  • 60-Month Beta 0.76
  • Price/Sales 5.83
  • Price/Cash Flow 12.78
  • Price/Book 12.84
Trade AMGN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 3.38
  • Number of Estimates 11
  • High Estimate 3.64
  • Low Estimate 3.09
  • Prior Year 3.64
  • Growth Rate Est. (year over year) -7.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.08 +11.55%
on 12/22/20
246.84 -0.55%
on 01/15/21
+14.96 (+6.49%)
since 12/15/20
3-Month
210.28 +16.74%
on 10/29/20
246.84 -0.55%
on 01/15/21
+10.48 (+4.46%)
since 10/15/20
52-Week
177.05 +38.66%
on 03/23/20
264.97 -7.35%
on 07/06/20
+3.79 (+1.57%)
since 01/15/20

Most Recent Stories

More News
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

NVS : 95.63 (+1.07%)
BMY : 66.54 (+0.79%)
AMGN : 245.49 (+1.58%)
BGNE : 345.00 (+2.69%)
Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform

Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries based in Durham, North Carolina, today announced the acquisition of NoviSci, Inc., a software...

AMGN : 245.49 (+1.58%)
Worldwide Hairy Cell Leukemia Drugs Industry to 2025 - Cumulative Impact of COVID-19

, /PRNewswire/ -- The report has been added to offering.

AMGN : 245.49 (+1.58%)
AZN : 51.34 (+0.10%)
SmarTrend Watching for Potential Pullback in Shares of Amgen Inc After 1.20% Gain

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $235.95 to a high of $240.62. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $240.35...

AMGN : 245.49 (+1.58%)
Amgen Inc Rises 1.20% on Heavy Volume: Watch For Potential Pullback

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $235.95 to a high of $240.62. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $240.35...

AMGN : 245.49 (+1.58%)
Look for Shares of Amgen Inc to Potentially Pullback after Yesterday's 1.20% Rise

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $235.95 to a high of $240.62. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $240.35...

AMGN : 245.49 (+1.58%)
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down

Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.

SNY : 49.39 (+0.73%)
MRK : 83.38 (+1.47%)
AMGN : 245.49 (+1.58%)
ESPR : 25.55 (-4.49%)
Insights on the Hairy Cell Leukemia Drugs Global Market to 2025 - Players Include Amgen, Astex Therapeutics and AstraZeneca Among Others

The "Hairy Cell Leukemia Drugs Market Research Report by Product Type (Chemotherapy Drug and Immunotherapy Drug), by Distribution Channel (Cancer Research Organization, Hospitals, Long Term Care Centers,...

AMGN : 245.49 (+1.58%)
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen

, /PRNewswire/ -- EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement,...

AMGN : 245.49 (+1.58%)
Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020

, /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer (WCLC) hosted by the International...

AMGN : 245.49 (+1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

3rd Resistance Point 255.03
2nd Resistance Point 250.94
1st Resistance Point 248.21
Last Price 245.49
1st Support Level 241.39
2nd Support Level 237.30
3rd Support Level 234.57

See More

52-Week High 264.97
Last Price 245.49
Fibonacci 61.8% 231.38
Fibonacci 50% 221.01
Fibonacci 38.2% 210.64
52-Week Low 177.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar